Secondly, targeting probes which can recognize tumor tissues by binding to specific membrane targets, like glucose transporters (GLUTs) or epidermal growth factor receptors (e.g., EGFR, HER2) [19], [20], [21], [22]. The gene discussed is EGFR; the disease is neoplasm.